Why the study?
What are the overall costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting?
What are the overall costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting?
Biologic agents represent the highest single cost associated with RA infusion care, but personnel, supplies, and overhead costs also contribute substantially (8%-16%).
Answers are grounded in this paper and cite their sources.
Biologics dominate RA infusion costs; model leaves open adaptable frameworks for hospital budgeting decisions.
PURPOSE: Many hospital-based infusion centers treat patients with rheumatoid arthritis (RA) with intravenous biologic agents, yet may have a limited understanding of the overall costs of infusion in this setting. The purposes of this study were to conduct a microcosting analysis from a hospital perspective and to develop a model using an activity-based costing approach for estimating costs associated with the provision of hospital-based infusion services (preparation, administration, and follow-up) in the United States for maintenance treatment of moderate to severe RA. METHODS: A spreadsheet-based model was developed. Inputs included hourly wages, time spent providing care, supply/overhead costs, laboratory testing, infusion center size, and practice pattern information. Base-case values were derived from data from surveys, published studies, standard cost sources, and expert opinion. Costs are presented in year-2017 US dollars. The base case modeled a hospital infusion center serving patients with RA treated with abatacept, tocilizumab, infliximab, or rituximab. FINDINGS: Estimated overall costs of infusions per patient per year were $36,663 (rituximab), $36,821 (tocilizumab), $44,973 (infliximab), and $46,532 (abatacept). Of all therapies, the biologic agents represented the greatest share of overall costs, ranging from 87% to $91% of overall costs per year. Excluding infusion drug costs, labor accounted for 53% to 57% of infusion costs. IMPLICATIONS: Biologic agents represented the highest single cost associated with RA infusion care; however, personnel, supplies, and overhead costs also contributed substantially to overall costs (8%-16%). This model may provide a helpful and adaptable framework for use by hospitals in informing decision making about services offered and their associated financial implications.
No takes yet. Share an insight, caveat, or question.
Schmier et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: